Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tiotropium bromide - Boehringer Ingelheim

Drug Profile

Tiotropium bromide - Boehringer Ingelheim

Alternative Names: BA-679-BR; HGP 1011; Spiriva; Spiriva HandiHaler; Spiriva Respimat; Tiotropium; Tiotropium bromide monohydrate; Tiotropium HFA BAI; Tiotropium hydrofluoroalkane breath actuated inhaler; Tiotropium Respimat®

Latest Information Update: 14 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antiasthmatics; Antibronchitics; Epoxy compounds; Esters; Small molecules; Thiophenes; Tropanes
  • Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease
  • Phase III Cystic fibrosis
  • Discontinued Lung cancer

Most Recent Events

  • 08 Apr 2021 No recent reports of Phase-III development reported for Asthma (Adjunctive treatment, In children) in Brazil (Inhalation)
  • 29 Aug 2018 Generic equivalent available in western Europe for Chronic obstructive pulmonary disease
  • 18 May 2018 Interim pharmacokinetics data from a phase III NinoTinA-asthma® trial in Asthma presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top